ArticleDrug safety2018
Interest in a Mobile App for Two-Way Risk Communication: A Survey Study Among European Healthcare Professionals and Patients.
Article in Drug safety, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 3 syntheses or guidelines pooled it, 34 citations in OpenAlex.
- An Awareness of Pharmacovigilance Among Healthcare Professionals Due to an Underreporting of Adverse Drug Reactions Issue: A Systematic Review of the Current State, Obstacles, and Strategy.Current drug safety · 2024Pooled it
- Sociotechnical Factors Affecting Patients' Adoption of Mobile Health Tools: Systematic Literature Review and Narrative Synthesis.JMIR mHealth and uHealth · 2022Pooled it
- Exploring failure of antimicrobial prophylaxis and pre-emptive therapy for transplant recipients: a systematic review.BMJ open · 2020Pooled it
- Adverse Drug Reaction Reporting Using a Mobile Device Application by Persons with Multiple Sclerosis: A Cluster Randomized Controlled Trial.Drug safety · 2021Trial
- Consumers' experiences and perspectives on reporting adverse drug reactions using digital tools: a qualitative study.International journal of clinical pharmacy · 2026Article
- Employing bibliometrics and natural language processing (NLP) to analyse real-world applications of adverse drug reaction.Exploratory research in clinical and social pharmacy · 2025Article
- Consumer views on the use of digital tools for reporting adverse drug reactions: a cross-sectional study.International journal of clinical pharmacy · 2025Article
- Consumers' knowledge and experiences of adverse drug reaction reporting in Australia: a national survey.European journal of clinical pharmacology · 2024Article
- Facilitators and Barriers to Uptake of the Med Safety Mobile App for Adverse Drug Reaction Reporting by Health Workers in Uganda: A Qualitative Study.Drug safety · 2023Article
- Thai stakeholders' awareness and perceptions of the patient adverse event reporting system for herbal medicines: a qualitative study.International journal of clinical pharmacy · 2023Article
- Mobile apps for quick adverse drug reaction report: A scoping review.Pharmacoepidemiology and drug safety · 2023Article
- A Mobile App Leveraging Citizenship Engagement to Perform Anonymized Longitudinal Studies in the Context of COVID-19 Adverse Drug Reaction Monitoring: Development and Usability Study.JMIR human factors · 2022Article
- Smartphone-based mobile applications for adverse drug reactions reporting: global status and country experience.BMC medical informatics and decision making · 2022Article
- Comparison of Patient Adverse Drug Reaction Reporting Systems in Nine Selected Countries.International journal of environmental research and public health · 2022Review
- Developing a Mobile Health Application to Communicate Adverse Drug Reactions - Preconditions, Assessment of Possible Functionalities and Barriers for Patients and Their General Practitioners.Journal of multidisciplinary healthcare · 2022Article
- Article
- Patient literacy and awareness of medicine safety.The International journal of pharmacy practice · 2020Article
- Workshop on the Italian Pharmacovigilance System in the International Context: Critical Issues and Perspectives.Drug safety · 2019Article
- Recommendations on the Use of Mobile Applications for the Collection and Communication of Pharmaceutical Product Safety Information: Lessons from IMI WEB-RADR.Drug safety · 2019Article
- Design Considerations in the Development of App-Based Oral Anticancer Medication Management Systems: a Qualitative Evaluation of Pharmacists' and Patients' Perspectives.Journal of medical systems · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionPreviously, an app has been developed for healthcare professionals (HCPs) and patients to report adverse drug reactions (ADRs) to national medicines agencies and to receive drug safety information.
objectiveThis study aimed to assess (1) European HCPs' and patients' interest in an app for this two-way risk communication; (2) their preferences and perceptions towards specific app characteristics; and (3) which HCPs and patients are particularly interested in the app. In addition, these aspects were studied specifically for the countries where such an app was already available, i.e. Croatia, The Netherlands, and The UK.
methodsEuropean HCPs and patients were asked to complete a web-based survey developed in the context of the Web-Recognizing Adverse Drug Reactions (Web-RADR) project. Data on app interest and preferences and perceptions towards app characteristics were analysed descriptively. Logistic regression analyses were conducted to assess the association of HCP characteristics and patient characteristics on the level of interest in the app (i.e. very interested vs. not/somewhat interested).
resultsIn total, 399 HCPs and 656 patients completed the survey. About half of the patients (48%; ranging from 38% from The Netherlands to 54% from The UK), and 61% of the HCPs (ranging from 42% from The Netherlands to 54% from The UK) were very interested in the app. A faster means of reporting ADRs and easier access to the reporting form were the main perceived benefits. HCPs and patients who already use a health app were particularly interested in the app (HCPs: odds ratio [OR] 3.52; 95% confidence interval [CI] 1.96-6.30, patients: OR 1.64; 95% CI 1.19-2.27).
conclusionsAn app is positively perceived by HCPs and patients for reporting ADRs quickly and for receiving drug safety information from national medicines agencies. In particular, HCPs and patients who already use other health apps were interested in the app.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.